Human Papillomavirus 16-Positive Cancers Market Insights, Epidemiology, and Market Forecast 2036 | DelveInsight

DelveInsight's "HPV16+ Cancers Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of the HPV16+ Cancers, historical and forecasted epidemiology, as well as the HPV16+ Cancers market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the HPV16+ Cancers Market Report @ https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from HPV16+ Cancers Market Report
• In May 2026, ApolloBio, INOVIO Pharmaceuticals' development partner in Greater China, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, an investigational DNA immunotherapy evaluated as a non-surgical treatment for high-grade cervical dysplasia associated with HPV types 16 and 18; the trial met its primary efficacy endpoint with histopathologic regression of lesions and targeted viral clearance, and ApolloBio plans to pursue a regulatory submission in China.
• In March 2026, Nykode announced that its randomized clinical trial (Abili-T) in 1L R/M head and neck cancer is on track to deliver meaningful interim results by 2027.
• In January 2026, BNT113 received Fast Track Designation from the US FDA for the treatment of HPV16+ HNSCC expressing PD-L1.
• PDS Biotechnology indicated in its 2026 corporate presentation that Phase II clinical data for PDS0101 in cervical cancer are expected to be reported in H2 2026.
• HPV16 remains the predominant oncogenic type, accounting for ≥60% in anogenital cancer sites and 44-91% in head and neck cancers.
• According to the CDC, about 91% of anal cancer cases in the United States are thought to be attributable to HPV infection.
• An estimated 26 million Americans have an oral HPV infection at any given time, of whom approximately 2,600 are infected with HPV16.
• The total incident cases of HPV16+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) in Japan were nearly 3,900 in 2025.
• The HPV16+ Cancers Companies include Merck, Bristol Myers Squibb, Merus, Nykode Therapeutics, Roche, PDS Biotechnology, BioNTech, Cue Biopharma, Transgene, and others.
• Promising HPV16+ Cancers Therapies include Petosemtamab (MCLA-158), Versamune HPV (PDS0101), BNT113, Abipapogene suvaplasmid (VB10.16), CUE-101, TG4001, and others.

Get a Free sample for the HPV16+ Cancers Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What are HPV16-Positive Cancers?
HPV16+ Cancers are virus-driven epithelial malignancies primarily caused by persistent infection with human papillomavirus type 16, one of the most oncogenic HPV strains responsible for a significant proportion of cervical cancers and head & neck squamous cell carcinomas, particularly oropharyngeal tumors. These cancers arise when viral oncoproteins E6 and E7 disrupt key tumor suppressor pathways, leading to uncontrolled cellular proliferation, genomic instability, and malignant transformation of epithelial cells. Diagnosis begins with clinical suspicion based on symptoms or screening findings, followed by confirmation through biopsy and histopathological examination, which typically reveals squamous cell carcinoma. Once malignancy is established, HPV16 status is determined using molecular and immunohistochemical methods, most commonly HPV DNA genotyping and p16 immunohistochemistry, with HPV E6/E7 mRNA testing sometimes used for more definitive evidence of active viral oncogene expression.

HPV16+ Cancers Epidemiology Segmentation in the 7MM
• Total Incident Cases of Selected Indications
• Total Incident Cases of Selected Indications by HPV Status
• Total Incident Cases of HPV16+ Cancers
• Gender-specific Incident Cases of HPV16+ Cancers
• Stage-specific Incident Cases of HPV16+ Cancers

Download the report to understand which factors are driving HPV16+ Cancers epidemiology trends @ https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

HPV16+ Cancers Approved Therapies
• Pembrolizumab (KEYTRUDA): Merck
KEYTRUDA is an anti-PD-1 therapy that increases the ability of the body's immune system to help detect and fight tumor cells. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes, which may affect both tumor cells and healthy cells. In October 2025, Merck announced that the European Commission approved KEYTRUDA as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment.

• Nivolumab (OPDIVO): Bristol Myers Squibb
OPDIVO is a PD-1 inhibitor administered via IV, marketed in the US since 2016 for HNSCC.

HPV16+ Cancers Pipeline Analysis
• Versamune HPV (PDS0101): PDS Biotechnology
PDS0101 is a novel investigational HPV-targeted immunotherapy that stimulates a potent targeted T-cell attack against HPV-positive cancers, given by simple SC injection in combination with other immunotherapies and cancer treatments. It is currently in Phase III development (VERSATILE-003) for HPV16-positive recurrent/metastatic head and neck cancer, having received FDA Fast Track Designation, and has completed a Phase II study in collaboration with the National Cancer Institute. According to the company, intellectual property rights are exclusive until 2042/2043.

• BNT113: BioNTech
BNT113 is an mRNA cancer vaccine candidate encoding the E6 and E7 oncoproteins frequently found in HPV16+ solid cancers, aiming to trigger a strong and precise immune response in patients with HPV16+ HNSCC.

HPV16+ Cancers Companies
Merck, Bristol Myers Squibb, Merus, Nykode Therapeutics, Roche, PDS Biotechnology, BioNTech, Cue Biopharma, Transgene, and others

Discover more about therapies set to grab major HPV16+ Cancers market share @ https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

HPV16+ Cancers Market Outlook
The HPV16+ Cancers market (2022-2036) is transitioning from a long-standing reliance on surgery, radiation, and platinum-based chemotherapy toward a more immunotherapy and antigen-targeted treatment paradigm. Preventive vaccination has also reshaped the landscape, with prophylactic HPV vaccines such as GARDASIL, GARDASIL 9, and CERVARIX reducing the incidence of HPV16-related cancers by preventing initial infection. The introduction of immune checkpoint inhibitors such as Pembrolizumab and Nivolumab has significantly improved survival outcomes and established immunotherapy as a cornerstone of care. Beyond approved therapies, the pipeline is rapidly expanding with HPV16-specific, mechanism-driven treatments, including Petosemtamab (Merus), PDS0101 (PDS Biotechnology), BNT113 (BioNTech), CUE-101 (Cue Biopharma), and TG4001 (Transgene), primarily focused on targeting HPV16 E6/E7 oncoproteins. Among approved therapies, Pembrolizumab is expected to remain a key revenue driver due to its broad use across cervical and head and neck cancers, while the entry of mid-to-late stage candidates such as BNT113, PDS0101, and CUE-101 is anticipated to intensify competition and accelerate the shift toward HPV16-targeted immunotherapies in the later stages of the forecast period.

Scope of the HPV16+ Cancers Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025
• Forecast Period: 2026-2036
• Base Year: 2026
• Coverage: 7MM (US; Germany, France, Italy, Spain, and the UK; Japan)
• HPV16+ Cancers Companies: Merck, Bristol Myers Squibb, Merus, Nykode Therapeutics, Roche, PDS Biotechnology, BioNTech, Cue Biopharma, Transgene, and others
• HPV16+ Cancers Therapies: Pembrolizumab (KEYTRUDA), Nivolumab (OPDIVO), Petosemtamab (MCLA-158), Versamune HPV (PDS0101), BNT113, CUE-101, TG4001, and others
• HPV16+ Cancers Therapeutic Assessment: HPV16+ Cancers current marketed and emerging therapies
• HPV16+ Cancers Market Dynamics: HPV16+ Cancers market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• HPV16+ Cancers Unmet Needs, KOL's views, Analyst's views, HPV16+ Cancers Market Access and Reimbursement

To know more about HPV16+ Cancers companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of HPV16+ Cancers
4. Key Events of HPV16+ Cancers
5. Epidemiology and Market Methodology of HPV16+ Cancers
6. HPV16+ Cancers Market Overview at a Glance
7. Disease Background and Overview of HPV16+ Cancers
8. Epidemiology and Patient Population of HPV16+ Cancers
9. Patient Journey of HPV16+ Cancers
10. Marketed Therapies of HPV16+ Cancers
11. Emerging Therapies of HPV16+ Cancers
12. HPV16+ Cancers: 7MM Analysis
13. Unmet Needs of HPV16+ Cancers
14. SWOT Analysis of HPV16+ Cancers
15. KOL Views of HPV16+ Cancers
16. Market Access and Reimbursement of HPV16+ Cancers
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.